Editorial: Drugmakers need to show costs behind drug prices

By The Herald Editorial Board

There is no shortage of outrageous examples of medication price hikes by pharmaceutical companies.

Take your pick (and swallow with a full glass of water): “Pharma Bro” Martin Shkrelli, who jacked the price of a drug used to treat patients with malaria and HIV by 5,000 percent; Mylan, which raised the price of its EpiPen auto-injector for life-threatening allergy attacks to $365 for a generic drug that normally costs a dollar a dose; and more recently drugmaker Kaleo, which has increased the price for a two-pack of its “talking” Naloxone auto-injector — used to halt opioid overdoses — from $690 in 2014 to $4,500 today.

Particularly suspicious was the timing of Kaleo’s latest increase for its Evzio device, which uses recorded instructions to guide anyone to deliver a measured dose of Naloxone to someone who has overdosed. The increase followed Congress’ passage last year of the Comprehensive Addiction and Recovery Act, which sought to increase the availability of the emergency drug, especially for rural communities, and provided $1 billion in federal grants to state and local governments to fight the opioid and heroin epidemic.

Senators, including Sen. Maria Cantwell, D-Washington, wrote Kaleo in early February, calling the increase “beyond exploitative.”

After each outrage, drugmakers typically provide vague justifications about the costs of research and development and make token offers of price discount programs, but there’s been little in the way of satisfying explanation for the rising cost of medications, many of them substantial if not as forehead-slapping infuriating as the examples above.

Among widely used drugs that have seen marked increases in costs include insulin, the antibiotic erythromycin and the antidepressant clomipramine HCL. A report by the U.S. Government Accountability Office last year found that a group of 315 generic drugs covered by Medicare Part D saw increases of at least 100 percent between 2010 to 2015, and some increased by 1,000 percent or more.

Recent legislation in the U.S. Senate and in the Washington Legislature may eventually shine a brighter light on pricing practices.

Last year, U.S. Sen. John McCain, R-Arizona, introduced the Fair Drug Pricing Act, which would require drugmakers who increase the price of a drug by more than 10 percent over the course of a year to disclose information behind the decision to the public, including what was spent on research and development, as well as advertising and marketing. The bill did not advance further than the committee stage, last year.

This year, Rep. June Robinson, D-Everett, and others have sponsored HB 1541, which would seek even more detail from pharmaceutical companies. The bill would direct the state Office of Financial Management to hire a contractor to collect and release information from drugmakers and release it to the public and lawmakers.

Cost and other data would be collected for the 25 most frequently prescribed medications, the 25 costliest prescription drugs and the 25 drugs with the highest annual increase. And 60 days before they intend to increase the price of a particular drug, drugmakers would be required to submit information on the drug’s pricing history for the last five years, the financial assistance provided by companies to consumers through rebates and coupons, and an economic justification for the price increase. That information would be required for drugs set to increase by 10 percent over a 12-month period or 25 percent over a 36-month period.

Pharmaceutical companies are correct that research and development have driven innovation in new medications, devices and treatments, but a lack of transparency that obscures the reasons for price increases fuels the public’s suspicion and resentment.

The information that the federal and state legislation seeks would allow the public, governments, health care providers and the health care insurance industry some clarity on costs and better leverage for negotiating fair prices for medications.

It might also reveal costs that many consumers, who only see their $10 to $30 co-pay, normally don’t realize until their insurance premiums are increased.

There’s a balance to be struck between allowing pharmaceutical companies the capital they need to continue research and development and providing safe and affordable medications that can save lives and keep people healthy.

A little more light on the actual costs involved will help.

Talk to us

More in Opinion

Editorial cartoons for Monday, March 27

A sketchy look at the news of the day.… Continue reading

Construction workers walk along the underside of the Lynnwood Link light rail tracks on Tuesday, March 29, 2022 in Lynnwood, Washington. (Olivia Vanni / The Herald)
Editorial: What’s needed to get Link light rail on track

Sound Transit needs to streamline its process, while local governments ready for rail and stations.

Cathlamet, the Washington State Ferry that crashed in Seattle last month, sits at the Port of Everett on Thursday, Aug. 25, 2022, in Everett, Washington. The ferry will require extensive repairs after a hard landing crumpled one corner of the boat at the Fauntleroy dock on July 28. (Ryan Berry / The Herald)
Editorial: State needs quicker route for its new ferries

‘Build in Washington’ can be scrapped as a mandate, while still counting benefits of in-state shipyards.

Department of Natural Resources regional manager Allen McGuire, left, and acting bolder unit forester Tyson Whiteid, right, stand next to marker on land recently purchased by the DNR for timber harvest on Wednesday, Sept. 25, 2019 in Gold Bar, Wash. (Olivia Vanni / The Herald)
Editorial: Use state forestlands to ‘farm’ carbon credits

Legislation would allow the DNR to sell carbon offsets to fund reforestation and other climate work.

Comment: We need to stop trying to beat computers at their game

We can’t match the machines on output or speed. And we shouldn’t try. Let humans do the human stuff.

Saunders: Easy Narcan access might normalize opioid overdoses

There’s a place for harm reduction, but the OD-reversing drug shouldn’t be widely distributed.

Comment: Why Trump’s detour in the bosom of chaos matters

Porn star Stormy Daniels may come out of this with more integrity than Trump could ever muster.

Comment: Republican’s patience with Trump may not be assured

Depending on which charges he faces and the reaction to them, his support could ebb, starting with independents.

The sun turns a deep red as it sets beyond the Port of Everett and the Olympic Mountains on a hazardously smoky evening on Sunday, Oct. 16, 2022, in Everett, Washington. Following the start of the Bolt Creek Fire and other wildfires in the region, air quality in Snohomish County was seemingly always hazardous through September and October. (Ryan Berry / The Herald)
Comment: Yours is not your father’s climate change

Your experience of climate change depends on your generation and that of your children and grandchildren.

Most Read